From The Stage

A Dose of Pharma and Biotech News: June 28, 2017

Posted by / / BioAgilytix Insight, Industry Update

BioAgilytix’s team is committed to keeping on the pulse of bioanalytical innovation in the pharmaceutical and biotechnology industries, and sharing these insights with you, our valued colleagues and customers. Here are some of the headlines we’ve been most interested in recently: Blood Biomarker Signals Huntington’s Disease Bioanalysis Zone, June 7, 2017 Researchers from University College London (UK) recently published a study report on their search for a Huntington’s disease biomarker (HD), which found that amplified levels of neurofilament light chain circulating in the blood were present in both HD patients…

Supreme Court Decision Creates an Opportunity for Biosimilar Developers

Posted by / / Biosimilars, Industry Update

The US Supreme Court reached a ruling last week that will allow biosimilar companies to launch new biosimilar drugs more quickly. The decision was unanimous that these companies will not need to provide the reference product sponsor with six months’ notice after US Food and Drug Administration (FDA) approval of their intention to launch a generic version of that biological drug. The case was brought to the Supreme Court over the biosimilar drug Zarxio, when the reference product sponsor and competing biosimilar developer disagreed over how language in the Biologics…

Leading the Way in Large Molecule Bioanalysis, Our Way

Posted by / / BioAgilytix Insight, CRO Selection

What makes BioAgilytix a different kind of bioanalytical CRO? It’s all in the way we do large molecule bioanalysis, and how we work together with pharmaceutical and biotechnology companies to accelerate the development of innovative biotherapeutics that can change and save patients’ lives. As you can see, our approach overcomes the common challenges that customers face when working with traditional CROs. Instead of settling for missed deadlines, little transparency, or hit-or-miss scientific quality, we take a uniquely different stance to help our customers address the most complex aspects of their…

The Evolving Treatment of Lung Cancer: From Combination Chemotherapy to Immune Checkpoint Inhibitors

Posted by / / Immunogenicity, Industry Update

Lung cancer quickly became the most common cancer worldwide in the last decade of the 20th century due to an increase in smoking rates. 1.8 million patients were diagnosed with the disease in 2012, and in the same year 1.6 million patients died from this cancer (1). However, in the last three decades milestones in treating both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) have been met and then improved upon or superseded. The first significant milestone in treating this disease came from combination chemotherapy for…